Review Papers - SAITO MANABU
-
Clinical pharmacogenetics in the treatment of schizophrenia
Saito M, Yasui-Furukori N, Kaneko S.
Nihon Shinkei Seishin Yakurigaku Zasshi. 2005.6
-
Thioridazine inhibits risperidone metabolism: A clinically relevant drug interaction
T Nakagami, N Yasui-Furukori, M Saito, K Mihara, T Kondo, S Kaneko
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 7 S397 - S397 2004.6
-
Paroxetine dose-dependent interaction with risperidone in chronic schizophrenic patients
M Saito, N Yasui-Furukori, T Nakagami, H Furukori, S Kaneko
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 7 S240 - S241 2004.6
-
Association between C3435T polymorphism at MDR1 gene and therapeutic response to bromperidol in schizophrenic patients
N Yasui-Furukori, M Chiba, M Saito, T Nakagami, A Kaneda, T Tateishi, S Kaneko
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 7 S235 - S235 2004.6
-
Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction
T Nakagami, N Yasui-Furukori, M Saito, K Mihara, R De Vries, T Kondo, S Kaneko
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY 19 ( 3 ) 179 - 179 2004.5
-
Establishment of new cloned enzyme donor immunoassays (CEDIA((R))) for haloperidol and bromperidol
H Furukori, N Yasui-Furukori, M Saito, Y Inoue, T Someya, S Kaneko, T Tateishi
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY 19 ( 3 ) 190 - 190 2004.5
-
Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia
M Saito, N Yasui-Furukori, K Mihara, J Miura, Y Inoue, T Kondo, S Kaneko
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY 19 ( 3 ) 179 - 179 2004.5